According to the study by Next Move Strategy Consulting, the growth of the Kyprolis Market is primarily driven by increasing prevalence of multiple myeloma, advancements in treatment options, and growing adoption of combination therapies. The rising awareness of the drug's efficacy, especially in patients with relapsed or refractory multiple myeloma, further boosts market demand.